

## Grifols' Board of Directors Announces Termination of Acquisition Discussions with Brookfield

**Barcelona, Spain, Nov. 27, 2024** – The Board of Directors of Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced the termination of discussions with Brookfield Capital Partners (UK) Limited (“Brookfield”) regarding a potential acquisition of Grifols shares.

This followed the statement on November 19 by the Board of Directors of Grifols, based on the recommendation of its Transaction Committee, that it would not recommend shareholders of the company to accept a potential offer from Brookfield with a valuation of €6.45 billion for the entirety of the company's outstanding share capital (comprising both Class A and Class B shares). This indicative, non-binding valuation from Brookfield implied a price of €10.50 per Class A share, which was deemed to significantly undervalue the company's fundamental prospects and long-term potential.

This assessment is supported by the company's robust financial performance, as highlighted in its Q3 2024 results, which demonstrate Grifols' strong fundamentals and its ability to capture substantial global demand across key markets. Year-to-date revenues increased by 9.1% at constant currency year-over-year, driven by solid results across all business divisions and also maintains a solid financial position. In recent months, Grifols has successfully reduced its leverage, following the repayment of senior secured debt after receiving €1.6 billion from the sale of a 20% equity stake in Shanghai RAAS, along with a notable improvement in EBITDA adjusted, which for the last twelve months reached €1.7bn.

This announcement comes after a comprehensive due diligence exercise has been conducted, with Brookfield granted access to all requested information. Throughout this period, Grifols provided full access to the company's data and management, which was sufficient to make an informed assessment of the company's fundamental value in the context of a potential public tender offer.

The Board of Directors and management team of Grifols remain fully committed to executing the company's strategic plan, which is focused on enhancing long-term value. In alignment with this commitment, Grifols will soon announce a Capital Markets Day, where it will present its strategic vision under new leadership, alongside key initiatives designed to unlock growth opportunities and drive sustained performance.

---

### MEDIA CONTACTS:

**Grifols Press Office**

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – +34 91 311 92 90

Raquel Lumbreras (Tel. +34 659 572 185)

[Raquel\\_lumbreras@duomocomunicacion.com](mailto:Raquel_lumbreras@duomocomunicacion.com)

Borja Gómez (Tel. + 34 659 572 185)

[Borja\\_gomez@duomocomunicacion.com](mailto:Borja_gomez@duomocomunicacion.com)

## Investors

Investors Relations & Sustainability

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

Tel. +34 93 571 02 21

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [grifols.com](http://grifols.com)

## LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this

legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.